Andrew Grierson

Dr Andrew Grierson is a Senior Lecturer in Neuroscience at the School of Medicine and Population Health, University of Sheffield, based at the Sheffield Institute for Translational Neuroscience (SITraN). His research focuses on molecular mechanisms of neurodegenerative diseases with translational applications.

His educational background includes:

• PhD in Molecular Genetics from the University of Sheffield (1991-1994)
• BSc in Genetics from the University of Sheffield (1988-1991)

Dr Grierson's work centers on axonal transport regulation in motor neurone disease (MND) and hereditary spastic paraplegia (HSP), utilizing zebrafish and mouse models to investigate disease mechanisms and therapeutic interventions. Current projects include HDAC6 inhibition studies for CMT2A and HSP, C9ORF72 protein function analysis in ALS, and spastin gene replacement therapy development. His laboratory emphasizes preclinical translation with strong industry and charity partnerships.

Analysis of his 15 most recent publications (2013-2022) reveals consistent focus on ALS/MND pathophysiology, with increasing emphasis on C9ORF72-related mechanisms, mitochondrial dysfunction, and therapeutic target validation. The work bridges basic molecular neuroscience and clinical applications, predominantly using in vivo models and translational biomarkers.

Dr Grierson supervises multiple PhD students and collaborates with Pamela Shaw and Bob Johnston at Sheffield. His research group includes technicians Katie Adamson and Gary Shaw, operating within SITraN's specialized facilities for neurodegenerative disease research.